The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Psoriasis is the result of uncontrolled keratinocyte proliferation, and its pathogenesis involves the dysregulation of the immune system. The interplay among cytokines released by dendritic, Th1, Th2, and Th17 cells leads to the phenotypical manifestations seen in psoriasis. Biological therapies target the cytokine-mediated pathogenesis of psoriasis and have improved patient quality of life. This review will describe the underlying molecular pathophysiology and biologics used to treat psoriasis. A review of the literature was conducted using the PubMed and Google Scholar repositories to investigate the molecular pathogenesis, clinical presentation, and current therapeutics in psoriasis. Plaque psoriasis’, the most prevalent subtype of psoriasis, pathogenesis primarily involves cytokines TNF-α, IL-17, and IL-23. Pustular psoriasis’, an uncommon variant, pathogenesis involves a mutation in IL-36RN. Currently, biological therapeutics targeted at TNF-α, IL-12/IL-23, IL-17, and IL-23/IL-39 are approved for the treatment of moderate to severe psoriasis. More studies need to be performed to elucidate the precise molecular pathology and assess efficacy between biological therapies for psoriasis. Psoriasis is a heterogenous, chronic, systemic inflammatory disease that presents in the skin with multiple types. Recognizing and understanding the underlying molecular pathways and biological therapeutics to treat psoriasis is important in treating this common disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early lesions may show less developed psoriasiform hyperplasia and a more prominent superficial perivascular lymphocytic infiltrate, while chronic plaques show the classic combination of regular epidermal hyperplasia, parakeratosis, hypogranulosis, neutrophilic microabscesses, and vascular remodeling.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Disease initiation is thought to begin when environmental triggers such as trauma, infection, stress, or drugs disturb the epidermal barrier and activate keratinocyte proliferation.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Under these triggers, keratinocytes become activated and release antimicrobial peptides, self-nucleic acids, and alarm mediators that are sensed by innate immune cells, particularly the dendritic cells, which act as antigen-presenting cells (APC) [21,22].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The histological pattern closely mirrors activation of the IL-23/Th17 axis, with IL-17- and IL-22-driven keratinocyte hyperproliferation, neutrophil recruitment, and angiogenesis.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neutrophilic collections represent important diagnostic clues.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [21]
Experimental — accuracy not yet measured
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review
Armstrong, A. W., & Read, C. (2020) · JAMA · doi:10.1001/jama.2020.4006 · Cited by 2,335 · cited 10×
“Additionally, extra-cutaneous manifestations, such as cholangitis, epigastric pain, cholestasis, arthritis, acute renal failure, and interstitial pneumonitis, warrant hospitalization [1,2,33,51].”
BackgroundInfluentialPsoriasis Pathogenesis and Treatment
Rendon, A., & Schäkel, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061475 · Cited by 2,064 · cited 11×
“Sci. 2021, 22, x FOR PEER REVIEW 3 of 23 secrete TNF-α and IL-23 [1,13].”
BackgroundInfluentialRitchlin, C. T., Colbert, R. A., & Gladman, D. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1505557 · Cited by 1,404
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
Parisi, R., Iskandar, I. Y. K., Kontopantelis, E., Augustin, M., Griffiths, C. E. M., & Ashcroft, D. M. (2020) · BMJ · doi:10.1136/bmj.m1590 · Cited by 1,187 · cited 1×
“10% in high-income Southern Latin American countries [4].”
BackgroundIL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
Sherlock, J. P., Joyce-Shaikh, B., Turner, S. P., Chao, C.-C., Sathe, M., Grein, J., Gorman, D. M., Bowman, E. P., McClanahan, T. K., Yearley, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2817 · Cited by 1,060 · cited 1×
“This subsequently promotes osteoproliferation, bone erosion, and inflammation [41,42].”
BackgroundPivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Boniface, K., Bernard, F.-X., Garcia, M., Gurney, A. L., Lecron, J.-C., & Morel, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3695 · Cited by 864 · cited 1×
“In vitro stimulation of ILC NCR+ produces IL-22, which is implicated in the pathogenesis of psoriasis, and increases the production of S100 AMPs [17,18].”
BackgroundGriffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60125-8 · Cited by 834 · cited 1×
“Two prospective, multi-center phase III, double-blind trials (UNCOVER-2 and UNCOVER-3) evaluated the efficacy of ixekizumab compared to etanercept and placebo in patients with moderate to severe psoriasis [82].”
BackgroundPhase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828 · cited 1×
“Two replicate, multi-center phase III, randomized, double-blind, placebo and active comparator-controlled trials (AMAGINE-2 and AMAGINE-3), evaluated the efficacy of ustekinumab compared to brodalumab 210 mg in patients with moderate to severe psoriasis [76].”
BackgroundReich, K., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Li, S., Shen, Y.-K., & Gordon, K. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.042 · Cited by 761
Gordon, K. B., Strober, B., Lebwohl, M., Augustin, M., Blauvelt, A., Poulin, Y., Papp, K. A., Sofen, H., Puig, L., Foley, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31713-6 · Cited by 678 · cited 1×
“Two replicate, multi-center, phase III randomized, double-blind, placebo and active comparator-controlled trials (UltIMMa-1 and UltIMMa-2), evaluated the efficacy of ustekinumab compared to risankizumab in patients with moderate to severe plaque psoriasis [75].”
BackgroundAlinaghi, F., Calov, M., Kristensen, L. E., Gladman, D. D., Coates, L. C., Jullien, D., Gottlieb, A. B., Gisondi, P., Wu, J. J., Thyssen, J. P., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.027 · Cited by 673
The pathogenesis of psoriatic arthritis
Veale, D. J., & Fearon, U. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30830-4 · Cited by 576
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31279-5 · Cited by 569
Management of psoriasis as a systemic disease: what is the evidence?
Korman, N. J. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18245 · Cited by 539 · cited 1×
“Over the past two decades, advances in the understanding of the underlying inflammatory molecular pathway in psoriasis have altered management [9].”
BackgroundPapp, K. A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R. G., Cather, J., Gottlieb, A. B., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14493 · Cited by 470 · cited 1×
“A multi-center phase III, double-blind, placebo-controlled study evaluated the efficacy of brodalumab in patients with moderate to severe psoriasis (AMAGINE-1) [88].”
BackgroundRaharja, A., Mahil, S. K., & Barker, J. N. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0257 · Cited by 443 · cited 8×
“Dimerization of JAK allows STAT to bind via a docking site, subsequently phosphorylating and activating STAT [1,24].”
BackgroundInfluentialSystemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
Bimekizumab versus Secukinumab in Plaque Psoriasis
Reich, K., Warren, R. B., Lebwohl, M., Gooderham, M., Strober, B., Langley, R. G., Paul, C., De Cuyper, D., Vanvoorden, V., Madden, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102383 · Cited by 424
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Papp, K., Gordon, K., Thaçi, D., Morita, A., Gooderham, M., Foley, P., Girgis, I. G., Kundu, S., & Banerjee, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1806382 · Cited by 420 · cited 4×
“Deucravacitinib uniquely binds to the TYK2 regulatory domain, which allows it to target the underlying pathogenesis of psoriasis through inhibition of the intracellular component of the IL-12, IL-23, and Type I interferon pathways [109,110].”
BackgroundInfluentialReich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S., Hsu, M.-C., Branigan, P., & Blauvelt, A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31773-8 · Cited by 381
Kalb, R. E., Fiorentino, D. F., Lebwohl, M. G., Toole, J., Poulin, Y., Cohen, A. D., Goyal, K., Fakharzadeh, S., Calabro, S., Chevrier, M., et al. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.0718 · Cited by 373 · cited 2×
“Particularly, adalimumab and infliximab have been associated with a higher risk for serious infections [64].”
BackgroundTeunissen, M. B. M., Munneke, J. M., Bernink, J. H., Spuls, P. I., Res, P. C. M., te Velde, A., Cheuk, S., Brouwer, M. W. D., Menting, S. P., Eidsmo, L., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.146 · Cited by 335 · cited 1×
“In vitro stimulation of ILC NCR+ produces IL-22, which is implicated in the pathogenesis of psoriasis, and increases the production of S100 AMPs [17,18].”
BackgroundPapp, K. A., Menter, M. A., Abe, M., Elewski, B., Feldman, S. R., Gottlieb, A. B., Langley, R., Luger, T., Thaci, D., Buonanno, M., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14018 · Cited by 327
Self-citationReich, K., Papp, K. A., Blauvelt, A., Langley, R. G., Armstrong, A., Warren, R. B., Gordon, K. B., Merola, J. F., Okubo, Y., Madden, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00125-2 · Cited by 315
Blauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
Venken, K., Jacques, P., Mortier, C., Labadia, M. E., Decruy, T., Coudenys, J., Hoyt, K., Wayne, A. L., Hughes, R., Turner, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07911-6 · Cited by 312 · cited 1×
“Γδ T cells and NKT cells are the primary cells suggested to produce IL-17 independent of IL-23 [38,44].”
BackgroundSystemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences
Boehncke, W.-H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00579 · Cited by 307
Reich, K., Gooderham, M., Thaçi, D., Crowley, J. J., Ryan, C., Krueger, J. G., Tsai, T.-F., Flack, M., Gu, Y., Williams, D. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30952-3 · Cited by 301
Gordon, K. B., Foley, P., Krueger, J. G., Pinter, A., Reich, K., Vender, R., Vanvoorden, V., Madden, C., White, K., Cioffi, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00126-4 · Cited by 295 · cited 1×
“Bimekizumab is another IL-17 inhibitor currently undergoing phase III trials [83].”
BackgroundClinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αβ T cell clones
Matos, T. R., O’Malley, J. T., Lowry, E. L., Hamm, D., Kirsch, I. R., Robins, H. S., Kupper, T. S., Krueger, J. G., & Clark, R. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93396 · Cited by 285
Egeberg, A., Ottosen, M. B., Gniadecki, R., Broesby-Olsen, S., Dam, T. N., Bryld, L. E., Rasmussen, M. K., & Skov, L. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16102 · Cited by 284 · cited 4×
“The safety profile for ustekinumab was consistent with past studies and supported its higher drug survival compared to TNF-α inhibitors [63,78].”
BackgroundResultInfluentialResolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells
Rauber, S., Luber, M., Weber, S., Maul, L., Soare, A., Wohlfahrt, T., Lin, N.-Y., Dietel, K., Bozec, A., Herrmann, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4373 · Cited by 282 · cited 3×
“Neutrophils, also recruited by the pro-inflammatory cytokines, lead to the activation of synoviocytes, angiogenesis, and osteoclast-induced bone destruction [37,41].”
BackgroundHerster, F., Bittner, Z., Archer, N. K., Dickhöfer, S., Eisel, D., Eigenbrod, T., Knorpp, T., Schneiderhan-Marra, N., Löffler, M. W., Kalbacher, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13756-4 · Cited by 267 · cited 6×
“Sci. 2021, 22, x FOR PEER REVIEW 3 of 23 secrete TNF-α and IL-23 [1,13].”
BackgroundInfluentialBimekizumab versus Adalimumab in Plaque Psoriasis
Warren, R. B., Blauvelt, A., Bagel, J., Papp, K. A., Yamauchi, P., Armstrong, A., Langley, R. G., Vanvoorden, V., De Cuyper, D., Cioffi, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102388 · Cited by 252
Old and New Biological Therapies for Psoriasis
Rønholt, K., & Iversen, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112297 · Cited by 240 · cited 2×
“Particularly, ustekinumab inhibits psoriasis pathogenesis through the IL-12/TH1 and IL-23/Th17 pathways (Table 2) (Table 3) [2,53,71,72].”
BackgroundKamata, M., & Tada, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051690 · Cited by 237 · cited 8×
“TNF-α can also induce apoptosis of osteoblasts via inhibition of Wnt signaling, which also subsequently decreases the capacity to repair bone [38].”
BackgroundInfluentialPsoriasis: from Pathogenesis to Targeted Therapies
Conrad, C., & Gilliet, M. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-018-8668-1 · Cited by 234 · cited 2×
“Secukinumab [55,57,67,80, 81,93,94] Monoclonal antibody that blocks IL-17A FDA approved Subcutaneous Injection Induction: 300 mg at weeks 0, 1, 2, 3, 4 Maintenance: 300 mg every 4 weeks Headache, nasopharyngitis, upper respiratory infections, mucocutaneous candidiasis PUVA sessions, premalignancy, demyelinating diseas…”
BackgroundThe regulation of JAKs in cytokine signaling and its breakdown in disease
Hammarén, H. M., Virtanen, A. T., Raivola, J., & Silvennoinen, O. (2019) · Cytokine · doi:10.1016/j.cyto.2018.03.041 · Cited by 217
Tsai, T.-F., Ho, J.-C., Song, M., Szapary, P., Guzzo, C., Shen, Y.-K., Li, S., Kim, K.-J., Kim, T.-Y., Choi, J.-H., et al. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.05.005 · Cited by 212
Warren, R. B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., & Paul, C. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19341 · Cited by 211
Generalized pustular psoriasis: a review and update on treatment
Hoegler, K. M., John, A. M., Handler, M. Z., & Schwartz, R. A. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14949 · Cited by 204 · cited 8×
“The pathogenesis of pustular psoriasis is similar to the general pathogenesis of plaque psoriasis; however, it can involve a unique mutation in IL356RRN [33].”
BackgroundInfluentialReich, K., Gooderham, M., Green, L., Bewley, A., Zhang, Z., Khanskaya, I., Day, R. M., Goncalves, J., Shah, K., Piguet, V., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14015 · Cited by 199
IL-12 protects from psoriasiform skin inflammation
Kulig, P., Musiol, S., Freiberger, S. N., Schreiner, B., Gyülveszi, G., Russo, G., Pantelyushin, S., Kishihara, K., Alessandrini, F., Kündig, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms13466 · Cited by 197 · cited 1×
“This is supported by data on the anti-psoriatic effects from IL-12 signaling in an imiquimod induced psoriatic-like skin inflammation model [72,97].”
Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics
Petit, R. G., Cano, A. C., Ortiz, A., Espina, M., Prat, J., Muñoz-Mateu, M., Severino, P. B., Souto, E. B., García, M. L., Pujol, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094983 · Cited by 195 · cited 3×
“, physical injury) can trigger and maintain the inflammatory pathway in psoriasis [11].”
BackgroundInfluentialKrueger, J. G., Wharton, K. A., Schlitt, T., Suprun, M., Torene, R. I., Jiang, X., Wang, C. Q., Fuentes-Duculan, J., Hartmann, N., Peters, T., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.04.029 · Cited by 188 · cited 3×
“Secukinumab [55,57,67,80, 81,93,94] Monoclonal antibody that blocks IL-17A FDA approved Subcutaneous Injection Induction: 300 mg at weeks 0, 1, 2, 3, 4 Maintenance: 300 mg every 4 weeks Headache, nasopharyngitis, upper respiratory infections, mucocutaneous candidiasis PUVA sessions, premalignancy, demyelinating diseas…”
BackgroundBimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
Adams, R., Maroof, A., Baker, T., Lawson, A. D. G., Oliver, R., Paveley, R., Rapecki, S., Shaw, S., Vajjah, P., West, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01894 · Cited by 188
AP1S3 Mutations Are Associated with Pustular Psoriasis and Impaired Toll-like Receptor 3 Trafficking
Setta-Kaffetzi, N., Simpson, M. A., Navarini, A. A., Patel, V. M., Lu, H.-C., Allen, M. H., Duckworth, M., Bachelez, H., Burden, A. D., Choon, S.-E., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.04.005 · Cited by 186 · cited 1×
“The AP1S3 mutation has been found predominantly in patients of European origin, and, in rare cases, in patients of East Asian origin [27,28].”
BackgroundYang, K., Oak, A. S. W., & Elewski, B. E. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00578-0 · Cited by 185 · cited 12×
“Particularly, PsA is an immune-mediated chronic inflammatory arthropathy that causes inflammation of the entheses and joints, characterized by immune cell infiltration and vascularization [36].”
BackgroundInfluentialBlauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K. B., Ferris, L. K., Langley, R. G., Tada, Y., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18851 · Cited by 175
Bai, F., Li, G. G., Liu, Q., Niu, X., Li, R., & Ma, H. (2019) · Journal of Immunology Research · doi:10.1155/2019/2546161 · Cited by 174 · cited 7×
“4%), and secukinumab 150 mg (31%) [92].”
BackgroundMethodInfluentialSystemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Doney, L., Dressler, C., Hua, C., Hughes, C., Naldi, L., Afach, S., & Le Cleach, L. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub4 · Cited by 170 · cited 1×
“Although consideration should be taken into account for the specific contraindications and black box warnings for each medication, the overall safety profiles of biologics are favorable [114].”
BackgroundJAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Nogueira, M., Puig, L., & Torres, T. (2020) · Drugs · doi:10.1007/s40265-020-01261-8 · Cited by 162 · cited 7×
“Activated STAT molecules, a transcription factor, then translocate to the nucleus to control gene expression, altering transcription to further propagate the inflammatory pathogenesis of psoriasis [25].”
BackgroundInfluentialSawyer, L. M., Malottki, K., Sabry-Grant, C., Yasmeen, N., Wright, E., Sohrt, A., Borg, E., & Warren, R. B. (2019) · PLOS ONE · doi:10.1371/journal.pone.0220868 · Cited by 161 · cited 1×
“Psoriasis occurs equally in both males and females and has a bimodal age of peak occurrence: between 20–30 and 60–70 [5,6].”
BackgroundFiorentino, D., Ho, V., Lebwohl, M. G., Leite, L., Hopkins, L., Galindo, C., Goyal, K., Langholff, W., Fakharzadeh, S., Srivastava, B., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.07.013 · Cited by 159 · cited 1×
“Further analysis of the PSOLAR registry analyzed the risk of malignancy with TNF-α inhibitor therapy compared to methotrexate and ustekinumab in patients with no history of cancer [65].”
MethodGottlieb, A. B., Blauvelt, A., Thaçi, D., Leonardi, C. L., Poulin, Y. P., Drew, J., Peterson, L., Arendt, C. H., Burge, D. J., & Reich, K. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.012 · Cited by 157 · cited 1×
“Although a higher proportion of patients achieved PASI-75 in a dose-dependent manner in the CIMPASI-1 trial, there was little difference between doses of certolizumab in the CIMPASI-2 trial [59].”
ResultMahil, S. K., Twelves, S., Farkas, K., Setta-Kaffetzi, N., Irvine, A. D., Gach, J. E., Irvine, A. D., Képíró, L., Mockenhaupt, M., Oon, H. H. B., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.06.618 · Cited by 153 · cited 1×
“The AP1S3 mutation has been found predominantly in patients of European origin, and, in rare cases, in patients of East Asian origin [27,28].”
BackgroundSugiura, K. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2014.02.006 · Cited by 141 · cited 2×
“However, studies analyzing the CARD14 and IL356RN mutation suggest generalized pustular psoriasis with plaque psoriasis and generalized pustular psoriasis alone have different etiologies [31,32].”
BackgroundTyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Szilveszter, K. P., Németh, T., & Mócsai, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01862 · Cited by 136 · cited 2×
“An activated JAK can then form a homodimer, by binding with a member of the same family, or heterodimer, by binding a JAK from another family [23].”
BackgroundMease, P. J., Helliwell, P. S., Hjuler, K. F., Raymond, K., & McInnes, I. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216835 · Cited by 131 · cited 12×
“Particularly, PsA is an immune-mediated chronic inflammatory arthropathy that causes inflammation of the entheses and joints, characterized by immune cell infiltration and vascularization [36].”
BackgroundInfluentialBiologic Treatments of Psoriasis: An Update for the Clinician
Brownstone, N. D., Hong, J. J., Mosca, M., Hadeler, E. K., Liao, W. J., Bhutani, T., & Koo, J. Y. M. (2021) · Biologics · doi:10.2147/btt.s252578 · Cited by 127 · cited 10×
“Brodalumab [53,67,70] FDA approved Approved Recommended by EMA”
BackgroundInfluentialBlauvelt, A., Leonardi, C., Elewski, B., Crowley, J. J., Guenther, L. C., Gooderham, M., Langley, R. G., Vender, R., Pinter, A., Griffiths, C. E. M., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19509 · Cited by 122
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions
Foley, P. A., Gordon, K. B., Griffiths, C. E. M., Wasfi, Y. S., Randazzo, B. P., Song, M., Li, S., Shen, Y., & Blauvelt, A. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.0793 · Cited by 122
Role of Innate Immune Cells in Psoriasis
Sato, Y., Ogawa, E., & Okuyama, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186604 · Cited by 113 · cited 9×
“γδ T cells specifically contain a TCR consisting of an γ and δ chain, contrary to classical T cell α and β chain, and are found in increased numbers in psoriatic skin lesions [12,15].”
BackgroundInfluentialSugiura, K., Muto, M., & Akiyama, M. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.46 · Cited by 109
Biologics for the primary care physician: Review and treatment of psoriasis
Schadler, E. D., Ortel, B. J., & Mehlis, S. L. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2018.06.001 · Cited by 104 · cited 7×
“IL-17 works via two different mechanisms: one is dependent on the cytoplasmic adaptor protein ACT1 and the other is independent of ACT1 [3].”
BackgroundInfluentialGilhar, A., Ullmann, Y., Assy, B., Shalaginov, R., Serafimovich, S., Kerner, H., & Kalish, R. S. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01812.x · Cited by 93 · cited 1×
“Moreover, transplantation of NKT cells leads to the induction of psoriasis, suggesting a contributory role in the pathogenesis of psoriasis [12,20].”
BackgroundPyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity
Watanabe, R., Shirai, T., Namkoong, H., Zhang, H., Berry, G. J., Wallis, B. B., Schaefgen, B., Harrison, D. G., Tremmel, J. A., Giacomini, J. C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92167 · Cited by 93 · cited 1×
“According to studies utilizing ultrasound imaging, the underlying inflammation is due to tenosynovitis and joint synovitis, while studies using magnetic resonance imaging have also suggested possible enthesitis [39,40].”
BackgroundZhang, J., Tsai, T.-F., Lee, M.-G., Zheng, M., Wang, G., Jin, H., Gu, J., Li, R., Liu, Q., Chen, J., et al. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.05.004 · Cited by 89 · cited 2×
“The most commonly reported treatment-emergent adverse events included upper respiratory tract infections, nasopharyngitis, and hyperlipidemia [112].”
BackgroundImmune responses and therapeutic options in psoriasis
Afonina, I. S., Nuffel, E. V., & Beyaert, R. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03726-1 · Cited by 89 · cited 2×
“Ultimately, an increased understanding has allowed for the development of biologics and small molecule inhibitors that selectively target psoriasis’ pathogenesis, increasing treatment efficacy while minimizing side effects [10].”
BackgroundInverse Psoriasis: From Diagnosis to Current Treatment Options
Micali, G., Verzì, A. E., Giuffrida, G., Panebianco, E., Musumeci, M. L., & Lacarrubba, F. (2020) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s189000 · Cited by 88 · cited 2×
“Inverse psoriasis can present in isolation or accompany plaque psoriasis [49].”
BackgroundAn update on genetic basis of generalized pustular psoriasis (Review)
Zhou, J., Luo, Q., Cheng, Y., Xia, W., & Liu, J. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4951 · Cited by 87 · cited 5×
“The unique mutation in IL356RN is specific to pustular psoriasis [33].”
BackgroundInfluentialArmstrong, A. W., Soliman, A. M., Betts, K. A., Wang, Y., Gao, Y., Puig, L., & Augustin, M. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00511-1 · Cited by 83 · cited 5×
“[61] The highest efficacy was reported in patients who received infliximab (56.”
BackgroundMethodInfluentialŠućur, A., Jajić, Z., Artuković, M., Matijašević, M. I., Anić, B., Flegar, D., Markotić, A., Kelava, T., Ivčević, S., Kovačić, N., et al. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1337-6 · Cited by 82 · cited 1×
“According to studies utilizing ultrasound imaging, the underlying inflammation is due to tenosynovitis and joint synovitis, while studies using magnetic resonance imaging have also suggested possible enthesitis [39,40].”
BackgroundReich, K., Rich, P. A., Maari, C., Bissonnette, R., Leonardi, C., Menter, A., Igarashi, A., Klekotka, P. A., Patel, D. R., Li, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17628 · Cited by 78 · cited 3×
“Mirikizumab, also an IL-23/IL-39 inhibitor, underwent phase III trials but was discontinued due to administrative purposes [98].”
BackgroundInfluentialRole of Janus Kinase Inhibitors in Therapy of Psoriasis
Słuczanowska-Głąbowska, S., Ziegler-Krawczyk, A., Szumilas, K., & Pawlik, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194307 · Cited by 77 · cited 2×
“Oral tofacitinib, is a JAK1 and JAK2 inhibitor and is the most studied oral JAK inhibitor in moderate to severe plaque psoriasis (Table 6) [108].”
BackgroundPsoriasis: Recent progress in molecular‐targeted therapies
Honma, M., & Hayashi, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15727 · Cited by 75 · cited 10×
“Brodalumab [53,67,70] FDA approved Approved Recommended by EMA”
BackgroundInfluentialKimball, A. B., Rothman, K. J., Kricorian, G., Pariser, D. M., Yamauchi, P. S., Menter, A., Teller, C. F., Aras, G. A., Accortt, N. A., Hooper, M. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.08.050 · Cited by 73 · cited 1×
“A five-year surveillance registry of psoriatic patients treated with etanercept did not identify any new safety signals, consistent with its current safety profile [62].”
BackgroundBiologics in the treatment of pustular psoriasis
Wang, W., & Jin, H. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1785427 · Cited by 66 · cited 1×
“Additionally, extra-cutaneous manifestations, such as cholangitis, epigastric pain, cholestasis, arthritis, acute renal failure, and interstitial pneumonitis, warrant hospitalization [1,2,33,51].”
BackgroundInterleukin 39: a new member of interleukin 12 family
Lu, Z., Xu, K., Wang, X., Li, Y., & Li, M. (2020) · Central European Journal of Immunology · doi:10.5114/ceji.2020.97911 · Cited by 62 · cited 1×
“IL-39, a heterodimer composed of IL-23p19 and Epstein-Barr virus-induced gene 3, is a new member of the IL-12 family and is targeted by p19 inhibitors [96].”
BackgroundChallenge of Nail Psoriasis: An Update Review
Ji, C., Wang, H., Bao, C., Zhang, L., Ruan, S., Zhang, J., Gong, T., & Cheng, B. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08896-9 · Cited by 54 · cited 7×
“Salmon patches appear as irregular yellow-orange discolored areas under the nail plate [48].”
BackgroundInfluentialBellinato, F., Gisondi, P., & Girolomoni, G. (2021) · Biologics: Targets and Therapy · doi:10.2147/btt.s290309 · Cited by 53 · cited 3×
“Deucravacitinib uniquely binds to the TYK2 regulatory domain, which allows it to target the underlying pathogenesis of psoriasis through inhibition of the intracellular component of the IL-12, IL-23, and Type I interferon pathways [109,110].”
Backgroundde Vries, A. C. Q., Thio, H. B., de Kort, W. J. A., Opmeer, B. C., van der Stok, H. M., de Jong, E. M. G. J., Horváth, B., Busschbach, J. J. V., Nijsten, T. E. C., & Spuls, P. I. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14867 · Cited by 52
Yeung, J., Gooderham, M., Grewal, P. S., Hong, C.-H., Lansang, P., Papp, K. A., Poulin, Y. P., Turchin, I., & Vender, R. B. (2020) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475420928376 · Cited by 51
Bagel, J., Blauvelt, A., Nia, J. K., Hashim, P. W., Patekar, M., de Vera, A., Ahmad, K. A., Paguet, B., Xia, S., Muscianisi, E., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16558 · Cited by 50 · cited 1×
“Another multicenter, phase IIIb randomized, double-blind, head-to-head parallel group trial evaluated the efficacy of ustekinumab compared to secukinumab in patients with moderate to severe psoriasis [77].”
BackgroundThomas, L., Azad, J., & Takwale, A. (2020) · Clinical and Experimental Dermatology · doi:10.1111/ced.14314 · Cited by 50 · cited 2×
“Psoriasis also commonly affects the nails, with an approximate lifetime incidence of 80–90% [47].”
BackgroundMenter, A., Thaçi, D., Wu, J. J., Abramovits, W., Kerdel, F. A., Arikan, D., Guo, D., Ganguli, A. X., Bereswill, M., Camez, A. A., et al. (2017) · Dermatology and Therapy · doi:10.1007/s13555-017-0198-x · Cited by 49 · cited 3×
“The safety profile for ustekinumab was consistent with past studies and supported its higher drug survival compared to TNF-α inhibitors [63,78].”
BackgroundResultQin, P., Zhang, Q., Chen, M., Fu, X., Wang, C., Wang, Z., Yu, G., Yu, Y., Li, X., Sun, Y., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.269 · Cited by 40 · cited 1×
“Moreover, a gain-of-function mutation of CARD14 causes overactivation of the NFκB pathway, which increases expression of pro-inflammatory cytokines IL-1, IL-6, IL-8, and TNF-α, facilitating keratinocyte proliferation and differentiation [31,33,34].”
BackgroundStein, K. R., Pearce, D. J., & Feldman, S. R. (2005) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2005.01.004 · Cited by 37
Self-citationKhosravi, H., Siegel, M. P., Voorhees, A. S. V., & Merola, J. F. (2017) · PubMed · Cited by 35
Review of phase III trial data on IL ‐23 inhibitors tildrakizumab and guselkumab for psoriasis
Amin, M., Darji, K., No, D. J., & Wu, J. J. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14451 · Cited by 34 · cited 3×
“I - , produced by mDCs, is bundantly found in psoriatic lesions and maintains Th17 cells, a major source of IL-17 [14].”
BackgroundCeccarelli, M., Rullo, E. V., Berretta, M., Cacopardo, B. S., Pellicanò, G. F., Nunnari, G., & Guarneri, C. (2020) · Dermatologic Therapy · doi:10.1111/dth.14660 · Cited by 31 · cited 1×
“Psoriasis occurs equally in both males and females and has a bimodal age of peak occurrence: between 20–30 and 60–70 [5,6].”
BackgroundClinical profiles of pediatric patients with GPP alone and with different IL36RN genotypes
Wang, Y., Cheng, R., Lu, Z., Guo, Y., Yan, M., Liang, J., Huang, P., Li, M., & Yao, Z. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.11.008 · Cited by 31 · cited 1×
“However, studies analyzing the CARD14 and IL356RN mutation suggest generalized pustular psoriasis with plaque psoriasis and generalized pustular psoriasis alone have different etiologies [31,32].”
BackgroundDiels, J., Thilakarathne, P. J., Cameron, C. G., McElligott, S. C., Schubert, A., & Puig, L. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18634 · Cited by 26
Biologics in the Treatment of Psoriasis: Clinical and Economic Overview
Poulin, Y. P., Langley, R. G. B., Teixeira, H. D., Martel, M.-J., & Cheung, S. (2009) · Journal of Cutaneous Medicine and Surgery · doi:10.2310/7750.2009.00021 · Cited by 26
Integrative Approach to Psoriasis Vulgaris
Ljubenović, M., Lazarević, V., Golubović, M., & Binić, I. (2017) · Holistic Nursing Practice · doi:10.1097/hnp.0000000000000180 · Cited by 26 · cited 4×
“Inverse psoriasis, also known as flexural or intertriginous psoriasis, is a variant of plaque psoriasis [45].”
BackgroundInfluentialA new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.
Tonini, A., Gualtieri, B., Panduri, S., Romanelli, M., & Chiricozzi, A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1398729 · Cited by 23 · cited 1×
“Plaques classically present on the scalp, trunk, gluteal folds, buttocks, and extensor surfaces of extremities, such as elbows and knees [2,45,46].”
BackgroundLi, L., You, J., Fu, X., Wang, Z., Sun, Y., Liu, H., & Zhang, F. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17392 · Cited by 21 · cited 1×
“The CARD14 mutation has also been found primarily in patients with generalized pustular psoriasis and plaque psoriasis [29,30].”
BackgroundAslam, N., Saleem, H., Murtazaliev, S., Quazi, S. J., & Khan, S. (2020) · Cureus · doi:10.7759/cureus.9812 · Cited by 18 · cited 1×
“Currently, there are 11 FDA-approved biologics to treat psoriasis targeting the important TNF-α/IL-23/IL-17 inflammatory axis [52].”
BackgroundAli, Z., Matthews, R., Al‐Janabi, A., & Warren, R. B. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1967748 · Cited by 18 · cited 12×
“Particularly, PsA is an immune-mediated chronic inflammatory arthropathy that causes inflammation of the entheses and joints, characterized by immune cell infiltration and vascularization [36].”
BackgroundInfluentialEvaluating topical JAK inhibitors as a treatment option for atopic dermatitis
Fardos, M. I., Singh, R., Perche, P. O., Kelly, K. A., & Feldman, S. R. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.1993061 · Cited by 18 · cited 1×
“Cytokine ligand and receptor mediated binding leads to receptor oligomerization and initiation of the underlying molecular pathway [22,23].”
BackgroundSelf-citationBagel, J., Tyring, S. K., Rice, K. C., Collier, D. H., Kricorian, G., Chung, J. B., Iles, J., Stolshek, B. S., Kaliyaperumal, A., & Papp, K. A. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15381 · Cited by 13 · cited 2×
“8) achieved PASI-75 after 12 weeks of treatment with etanercept [58].”
BackgroundResultBovenschen, H. J., Gerritsen, W. J., van Rens, D. W. A., Seyger, M. M. B., de Jong, E. M. G. J., & van de Kerkhof, P. C. M. (2006) · Archives of Dermatological Research · doi:10.1007/s00403-006-0716-7 · Cited by 12
Küster, D., Nast, A., Gerdes, S., Weberschock, T. B., Wozel, G., Gutknecht, M., & Schmitt, J. M. (2016) · Archives of Dermatological Research · doi:10.1007/s00403-016-1634-y · Cited by 11
Research works printed but not linked: 1
- Badri, 2021, Plaque Psoriasis, StatPearls, 19, 560
Cited by
Oxidative Stress: Signaling Pathways, Biological Functions, and Disease
Liu, S., Liu, J., Wang, Y., Deng, F., & Deng, Z. (2025) · MedComm · doi:10.1002/mco2.70268 · Cited by 359
Inflammation and Psoriasis: A Comprehensive Review
Matei-Man, A.-M., Orăsan, M. S., Hoteiuc, O.-A., Olănescu-Vaida-Voevod, M.-C., & Mocan, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216095 · Cited by 134
“%) and murine variable region (25%), binding to both soluble and transmembrane forms of TNF-α and thus disrupting the interaction of TNF-α with its receptors [179,180].”
BackgroundUpdated Perspectives on Keratinocytes and Psoriasis: Keratinocytes are More Than Innocent Bystanders
Ortiz‐López, L. I., Choudhary, V., & Bollag, W. B. (2022) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s327310 · Cited by 109
“Such considerations are important since psoriatic individuals are often dissatisfied with current therapies(115) because some may be ineffective and others, like the biologic agents, can be expensive and exhibit a spectrum of undesirable side effects, for example, increasing the risk of serious infections and possibly…”
BackgroundNanocarrier-Based Transdermal Drug Delivery Systems for Dermatological Therapy
Kang, Y., Zhang, S., Wang, G., Yan, Z., Wu, G., Tang, L., & Wang, W. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111384 · Cited by 100
Gasdermin D-mediated keratinocyte pyroptosis as a key step in psoriasis pathogenesis
Lian, N., Chen, Y., Chen, S., Zhang, Y., Chen, H., Yang, Y., Gu, H., Chen, Q., Li, M., & Chen, X. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06094-3 · Cited by 76
Metadata
- Authors
- Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R.
- Affiliations
- Wake Forest University Health Sciences (US)
- Corresponding author
- Feldman, Steven R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-11-26
- Volume
- 22
- Issue
- 23
- Pages
- 12793
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8657643
- OpenAlex
- W3216061490
- Cited by
- 192
- References
- 104
- Citations by year
- 2026: 48 · 2025: 44 · 2024: 57 · 2023: 31 · 2022: 12
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- psoriasis, cytokines, molecular pathogenesis, TNF-α, IL-17, IL-23, pustular psoriasis, plaque psoriasis, biologic therapy, IL-12/IL-23, IL-39, inflammatory skin diseases
- MeSH terms
- Animals, Humans, Immunotherapy, Psoriasis, Quality of Life, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
